XOMA Corporation

XOMA Corporation is a biotechnology company whose business model is built on developing and licensing antibody-based therapeutics. The drug discovery and development process for such products inherently requires animal testing for preclinical research and regulatory compliance. As noted by Cruelty Free Investors, the company's operations fall under the animal exploitation category due to this reliance on animal models.

The company’s historical pipeline and platform, which focuses on discovering and developing innovative antibody therapeutics, involves extensive preclinical testing in animals. For example, past development work included programs against animal and human prolactin receptors, a process that necessitates animal studies. While specific recent testing volumes or violations are not detailed in the gathered evidence, the core business of biotherapeutic development places XOMA within the scope of companies that commercially exploit animals through testing.